Clinical Trials Logo

Recurrent Bladder Cancer clinical trials

View clinical trials related to Recurrent Bladder Cancer.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01382706 Terminated - Clinical trials for Stage IV Bladder Cancer

Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder

Start date: June 13, 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving docetaxel and lapatinib ditosylate together as second-line therapy works in treating patients with stage IV bladder cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving docetaxel and lapatinib ditosylate together may kill more tumor cells.

NCT ID: NCT01118351 Terminated - Clinical trials for Transitional Cell Carcinoma of the Bladder

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Start date: October 2008
Phase: Phase 2
Study type: Interventional

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well sunitinib malate works in treating patients with recurrent transitional cell bladder cancer.

NCT ID: NCT01108003 Terminated - Clinical trials for Transitional Cell Carcinoma of the Bladder

Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery

Start date: April 2010
Phase: N/A
Study type: Interventional

Rationale: Broccoli sprout extract contains ingredients that may prevent or slow the growth of certain cancers. Purpose: This pilot study is studying the side effects of broccoli sprout extract in treating patients with transitional cell bladder cancer undergoing surgery.

NCT ID: NCT00112905 Terminated - Clinical trials for Stage IV Bladder Cancer

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium

Start date: October 2005
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well sorafenib works in treating patients with progressive regional or metastatic cancer of the urothelium. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

NCT ID: NCT00004856 Terminated - Clinical trials for Stage IV Bladder Cancer

Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium

Start date: July 2002
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of trastuzumab in treating patients who have previously treated, locally advanced, or metastatic cancer of the urothelium. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.